Business
fromwww.theguardian.com
1 day agoTime for Reeves to recognise reality: AstraZeneca has killed stamp duty on shares | Nils Pratley
AstraZeneca's New York primary listing widens US investor access while causing roughly £200m annual UK stamp-duty losses, exposing flaws in the current stamp duty regime.